Abstract
Pegylated liposomal doxorubicin (PLD) has emerged as a recent innovation within the realm of antineoplastic agents, distinguished by its incorporation of doxorubicin within the liposomal bilayer. Given the low risk of cardiotoxicity, the clinical use of PLD has been expanding. We encountered a patient who underwent extended PLD therapy for recurrent malignancy and subsequently developed PLD-associated thrombotic microangiopathy, which was diagnosed by a detailed pathophysiological assessment. This case underscores the importance of considering thrombotic microangiopathy as a potential differential diagnosis in patients presenting with unexplained hypertension and renal impairment during prolonged PLD monotherapy.
Original language | English |
---|---|
Pages (from-to) | 2839-2845 |
Number of pages | 7 |
Journal | Internal Medicine |
Volume | 63 |
Issue number | 20 |
DOIs | |
State | Published - 2024 |
Keywords
- drug induced kidney injury
- liposome
- ovarian cancer
- polyethylene glycol (PEG)
- proteinuria
ASJC Scopus subject areas
- Internal Medicine